Compugen Ltd. (NASDAQ:CGEN - Get Free Report) was the target of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 2,090,000 shares, a growth of 11.8% from the March 15th total of 1,870,000 shares. Based on an average daily trading volume, of 651,500 shares, the days-to-cover ratio is presently 3.2 days.
Hedge Funds Weigh In On Compugen
Hedge funds have recently modified their holdings of the stock. Virtu Financial LLC bought a new position in shares of Compugen in the 1st quarter valued at about $37,000. Janney Montgomery Scott LLC grew its holdings in shares of Compugen by 58.4% in the 4th quarter. Janney Montgomery Scott LLC now owns 21,700 shares of the biotechnology company's stock valued at $43,000 after acquiring an additional 8,000 shares in the last quarter. Advisor Group Holdings Inc. grew its holdings in shares of Compugen by 29.3% in the 1st quarter. Advisor Group Holdings Inc. now owns 27,241 shares of the biotechnology company's stock valued at $87,000 after acquiring an additional 6,174 shares in the last quarter. Envestnet Asset Management Inc. grew its holdings in shares of Compugen by 23.4% in the 1st quarter. Envestnet Asset Management Inc. now owns 33,260 shares of the biotechnology company's stock valued at $111,000 after acquiring an additional 6,299 shares in the last quarter. Finally, Mariner LLC grew its holdings in shares of Compugen by 207.3% in the 4th quarter. Mariner LLC now owns 36,831 shares of the biotechnology company's stock valued at $26,000 after acquiring an additional 24,844 shares in the last quarter. Institutional investors own 12.22% of the company's stock.
Compugen Price Performance
CGEN stock traded down $0.13 during trading hours on Friday, reaching $2.13. 388,383 shares of the stock were exchanged, compared to its average volume of 259,174. The firm's 50-day moving average is $2.48 and its 200-day moving average is $1.64. The company has a market cap of $184.50 million, a price-to-earnings ratio of -9.68 and a beta of 2.63. Compugen has a 12 month low of $0.53 and a 12 month high of $3.03.
Compugen (NASDAQ:CGEN - Get Free Report) last released its earnings results on Tuesday, March 5th. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $0.01. The firm had revenue of $33.46 million for the quarter, compared to the consensus estimate of $60.00 million. As a group, equities research analysts forecast that Compugen will post 0.02 earnings per share for the current year.
Analyst Ratings Changes
Several analysts recently commented on CGEN shares. StockNews.com raised Compugen from a "hold" rating to a "buy" rating in a research note on Wednesday, March 6th. Stifel Nicolaus raised their price objective on Compugen from $3.00 to $4.00 and gave the stock a "buy" rating in a research note on Tuesday, December 19th.
Check Out Our Latest Analysis on Compugen
Compugen Company Profile
(
Get Free Report)
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Compugen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compugen wasn't on the list.
While Compugen currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
